Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Kína
64 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Beijing, Chongqing, Guangzhou, Jinan, Lanzhou, Shanghai, Shenzhen
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 1. fázisTaking peopleA Study of ATG-201 in Adult Participants With Autoimmune Diseases
- Where
- Beijing, Bengbu, Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Luoyang, Nanjing, Shanghai, Suzhou, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 149
- Run by
- Antengene Biologics Limited
See details and how to joinNCT07732309 - No phaseTaking peopleAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647 - 1. fázisTaking peopleA Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721 - 1. fázisTaking peopleA Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Therorna
See details and how to joinNCT07413341 - 3. fázisTaking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Sichuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xuzhou, Zhuzhou
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
- Where
- Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang
- Életkor
- 18 év to 65 év
- People
- 44 worldwide
- Run by
- Prolium Bioscience, Inc
See details and how to joinNCT07641634 - Korai 1. fázisTaking peopleClinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 10
- Run by
- Peking University Third Hospital
See details and how to joinNCT07301164 - No phaseTaking peopleClinical Cohort Study of Systemic Sclerosis
- Where
- Beijing
- Életkor
- Up to 100 év
- People
- 150
- Run by
- Peking University Third Hospital
See details and how to joinNCT07836361 - 1/2. fázisTaking peopleSafety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 9
- Run by
- Peking University Third Hospital
See details and how to joinNCT06828042 - 3. fázisTaking peopleA Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- Where
- Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
- Életkor
- 18 év and over
- People
- 514 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06716606 - 2/3. fázisTaking peopleA Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- Where
- Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai, Shenyang, Xi'an, Zhuzhou
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01 - Korai 1. fázisNot yet taking people in KínaNebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 18
- Run by
- Qiubai Li
See details and how to joinNCT07806045 - No phaseCsak meghívásosMass Spectrometry-based Immune Profiling in Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 500
- Run by
- Peking University People's Hospital
See details and how to joinNCT07188285 - 1. fázisTaking peopleEfficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
- Where
- Hefei
- Életkor
- 18 év to 69 év
- People
- 30
- Run by
- Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT06801119 - 1. fázisNot yet taking people in KínaSafety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
- Where
- Hefei
- Életkor
- 18 év to 69 év
- People
- 12
- Run by
- Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07523282 - 2. fázisNot yet taking people in KínaA Phase II Study of TollB-001 Tablets in Systemic Sclerosis
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 36
- Run by
- Toll Biotech Co. Ltd. (Beijing)
See details and how to joinNCT07745725 - 1/2. fázisTaking peopleCD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
- Where
- Beijing
- Életkor
- 10 év to 65 év
- People
- 45
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06947460 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680 - Korai 1. fázisTaking peopleMTS109 in Patients With Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07526350 - 1. fázisNot yet taking people in KínaA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Qingdao
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266 - Korai 1. fázisNot yet taking people in KínaRD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
- Where
- Hangzhou, Nanjing
- Életkor
- 5 év to 20 év
- People
- 30
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147 - Korai 1. fázisTaking peopleCD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
- Where
- Hangzhou
- Életkor
- 3 év and over
- People
- 15
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07586267 - No phaseTaking peopleExploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 72
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07558850